Carbon capture in mineral to be used as low emission raw material in green cement
The Qilu-Shengli Oilfield CCUS project in China will reduce carbon emission by 1 million tons per year
Ib will assume new role as CFO from February 1, 2022
Company is investing a low three-digit million euro amount to increase the capacity for these products by around 30 percent
Certification of sites at Antwerp and Ludwigshafen paves the way for the audited production of recycling- and bio-attributed styrenics materials using a mass balance approach
Acquisition will help Vertellus expands its European production capabilities and extends its reach in high-growth end markets
The ABS production capacity in Wingles will be 50,000 tonnes per year, to help meet the increased demand for ABS in Europe in industries such as Construction, Compounding, Household and Automotive
The company has reported total income of Rs. 386.43 crores during the period ended December 31, 2021.
The company has reported total income of Rs. 383.55 crores during the period ended December 31, 2021.
He will step down from the position of Chairman/Director of the company on 11th Feb
From 2004 till August 2020 he was the Chairman of the Sanmar Group Corporate Board
Customer and supplier centric approach by companies, self-regulation by industry, collaboration between stakeholders, and sustainable innovation among the key drivers
Expects required relief and incentives from the Budget 2022-23 that will accelerate the pace of the growth of industry.
Petronas and JAPEX will perform technical maturation activities to unlock potential CCS solutions.
ArborXD empowers energy industry carbon-conscious decision making
Inorganics Chemicals division’s revenue grew by 45% to Rs. 765 crore in Q3 FY22
Company received the ISCC PLUS certification to produce TPE materials with certified bio +/or bio-circular content via the mass balance approach at their Åmål, Sweden site
Fourth quarter 2021 EBITDA was $1.4 billion, or $2.0 billion excluding LCM and impairment
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The company has reported total income of Rs. 100.34 crores during the period ended December 31, 2021.
Subscribe to our newsletter & stay updated.
